Evidence map›Paper›PMID 41142435›Full record

ReviewMaterials today. Bio2025

Multifunctional nanoplatforms for tumor microenvironment remodeling: Toward precision and intelligent cancer therapy.

Xiangying Deng, Xinglong Liu, Lin Zhao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xiangying DengInstitute of Medical Sciences, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Xinglong LiuDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 41001l, China.
Lin ZhaoDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 41001l, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor heterogeneity and therapeutic resistance remain formidable obstacles to effective cancer treatment. Remodeling the tumor microenvironment (TME)-which is characterized by hypoxia, acidosis, immunosuppression, and extracellular matrix (ECM) remodeling-has emerged as a promising strategy to overcome these barriers. In recent years, nanotechnology has enabled the development of multifunctional and stimuli-responsive platforms for targeted TME modulation. Inorganic, organic, and hybrid nanocarriers leverage enhanced permeability and retention (EPR) effects, surface ligand engineering, and responsive elements to achieve spatiotemporally controlled drug and gene delivery. These advanced nanoplatforms can simultaneously normalize tumor vasculature, reverse hypoxia, modulate immune suppression, and degrade the ECM, thereby sensitizing tumors to conventional and emerging therapies. Integrating these TME-oriented strategies with photothermal and photodynamic therapy, immunotherapy, and metabolic reprogramming allows the construction of comprehensive, multimodal treatment systems. Furthermore, the convergence of intelligent nanomaterials and artificial intelligence (AI)-guided precision delivery is fostering the concept of therapeutic ecosystems, which enable dynamic treatment feedback and personalized tumor management. This review systematically summarizes the recent progress in nanotechnology-driven TME remodeling, highlights representative mechanisms and design strategies for multifunctional nanoplatforms, and discusses future opportunities and challenges in the development of intelligent, patient-centric cancer therapy systems.

Indexed as

AI-therapeutic ecosystemImmunotherapyNanomedicineStimuli-responsive deliveryTumor microenvironment

Identifiers

PMID41142435
PMCPMC12549778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.